Introduction
Results
Primary cell lines differ in their response to anti-tumor drugs
Clonogenic assay | Acute cytotoxic assay | Count | Mean | Median | Minimum | Maximum | EC50 ratio |
---|---|---|---|---|---|---|---|
Vincristine | 16 | 0.264 | 0.082 | 0.0002 | 2.5 | 12,500 | |
Cisplatin | 16 | 1.330 | 0.760 | 0.020 | 5.0 | 250 | |
Camptothecin | 16 | 0.783 | 0.160 | 0.001 | 5.0 | 5,000 | |
Mitomycin C | 16 | 0.053 | 0.007 | 0.00004 | 0.450 | 11,250 | |
Etoposide | 16 | 3.843 | 1.333 | 0.016 | 30 | 1,875 | |
Doxorubicin | 16 | 0.028 | 0.018 | 0.001 | 0.079 | 79 | |
Vincristine | 18 | 29.038 | 5.000 | 0.080 | 100 | 1,250 | |
Cisplatin | 18 | 12.333 | 4.750 | 2.600 | 45 | 17.3 | |
Camptothecin | 18 | 2.552 | 0.395 | 0.040 | 15 | 375 | |
Mitomicin C | 18 | 1.782 | 0.550 | 0.050 | 7 | 140 | |
Etoposide | 18 | 62.111 | 46.500 | 14.000 | 300 | 21.4 | |
Doxorubicin | 18 | 3.253 | 0.535 | 0.150 | 25 | 166.7 |
Primary cell lines are more sensitive to cisplatin when the frequency of EGR-1 positive cells in the tumor is lower
EGR-1 expression, mutations in oncosoppressive genes and drug cytotoxicity
Cell lines without mutations | Cell lines with mutations | ||||
---|---|---|---|---|---|
A
|
B
|
C
|
D
| ||
Lower
IK EGR-1
n = 6
|
Higher
IK EGR-1
n = 6
|
Total
n = 12
|
Total
n = 6
| ||
Xa = 22.33 | Xa = 48.33 | Xa = 35.33 | Xa = 54.66 | ||
Vincristine | Cb |
0.069
|
0.664
| 0.339 | 0.098 |
Ac | 27.31 | 21.21 | 24.27 | 38.58 | |
Cisplatin | C |
0.427
|
1.960
| 1.124 | 1.784 |
A | 15.73 | 16.83 | 16.3 | 4.433 | |
Camptothecin | C | 0.472 | 1.914 |
1.127
|
0.025
|
A | 2.783 | 2.992 | 2.887 | 1.881 | |
Mitomycin C | C | 0.089 | 0.09 |
0.075
|
0.002
|
A |
3.218
|
0.413
| 1.82 | 1.715 | |
Etoposide | C | 0.819 | 1.904 |
1.312
|
9.410
|
A | 50.16 | 50.66 | 50.41 | 85.50 | |
Doxorubicin | C | 0.021 | 0.035 | 0.027 | 0.028 |
A | 0.758 | 4.180 | 2.47 | 4.820 |